Share
GHK-Cu vs AHK-Cu: Which Copper Peptide Fits Your Formula?
Identity, Evidence, Skin vs Scalp Fit, Formulation Readiness and Development Risk
For formulators, product developers and cosmetic brands | Last reviewed: September 2026
About This Guide
This guide compares GHK-Cu and AHK-Cu as two distinct copper-binding tripeptides for cosmetic development. It combines current PHYTVA product documentation with peer-reviewed literature and keeps the evidence bases separate. The goal is not to name a universal winner; it is to help a formulation team choose the peptide whose identity, research fit, formulation maturity and commercial story best match the product brief.
- The difference between GHK-Cu and AHK-Cu in one minute
- How their peptide sequences differ
- Which peptide has the broader published evidence base
- Why AHK-Cu is more directly associated with hair-follicle research
- Which peptide fits a skin-care brief
- Which peptide fits a scalp/hair-care brief
- How formulation readiness and documentation affect the decision
- A decision matrix for choosing what to prototype first
Choose GHK-Cu first when the brief is facial skin care, general cosmetic copper-peptide development, or a program that benefits from the broader published GHK-Cu literature and a more mature formulation framework. Evaluate AHK-Cu when the brief is specifically scalp or fuller-looking-hair development and you want a copper peptide with direct human-hair-follicle ex-vivo and dermal-papilla-cell research. Do not call AHK-Cu clinically superior for hair, and do not assume GHK-Cu skin evidence transfers to AHK-Cu. No strong direct human head-to-head comparison establishes a universal winner.
1. GHK-Cu vs AHK-Cu: Quick Comparison
| Decision Factor | GHK-Cu | AHK-Cu | What It Means for Development |
|---|---|---|---|
| Peptide sequence | Gly-His-Lys + Cu | Ala-His-Lys + Cu | They are different copper-binding tripeptides |
| Current PHYTVA format | 99% blue powder | 99% blue powder | Both support measured R&D work |
| Published research depth | Broader and more diverse | Narrower | GHK-Cu gives more literature for general technical framing |
| Most distinctive evidence fit | Skin / cosmetic / regenerative research context | Human hair follicle ex vivo + dermal papilla in vitro | AHK-Cu has a clearer hair-follicle research identity |
| Direct GHK-vs-AHK human comparison | Not established | Not established | Do not rank universal potency |
| Formulation maturity | More developed practical guidance | Less independently established | AHK-Cu requires more grade-specific confirmation |
| Best first brief | Skin-care / broad copper-peptide development | Scalp / hair-care research-led concept | Choose by brief, not by marketing hype |
If your product brief simply says 'use a copper peptide,' start with GHK-Cu because the evidence and formulation framework are more developed. Move to AHK-Cu when the product brief specifically benefits from AHK-Cu's hair-follicle research identity or when a differentiated scalp-peptide story is strategically important.
2. They Are Not the Same Peptide
GHK-Cu uses the Gly-His-Lys sequence; AHK-Cu uses Ala-His-Lys. Only the first amino acid changes, but that is enough to make them different peptide identities with different evidence bases.
| Peptide | Sequence | Current PHYTVA Product Identity |
|---|---|---|
| GHK-Cu | Gly-His-Lys complexed with copper | GHK-Cu / Copper Tripeptide-1, 99% blue powder |
| AHK-Cu | Ala-His-Lys complexed with copper | L-alanyl-L-histidyl-L-lysine copper(II) complex, 99% blue powder |
AHK-Cu is commonly marketed in the cosmetic raw-material market as Copper Tripeptide-3. For regulatory documentation, use the naming and identity information supplied for the exact commercial grade rather than assuming every market name maps to an identical complex basis.
3. How Strong Is the Evidence for Each?
GHK-Cu has the broader research footprint. Recent reviews discuss its physicochemical behavior, skin delivery, extracellular-matrix biology and topical cosmetic interest; however, the literature still contains fewer standardized human topical trials than marketing claims often imply. [1]
AHK-Cu has a much narrower evidence base, but one study is directly relevant to hair biology. Pyo and colleagues exposed isolated human hair follicles ex vivo and cultured dermal papilla cells in vitro to AHK-Cu. The study reported increased follicle elongation and dermal-papilla-cell proliferation at laboratory concentrations. [2]
Those AHK-Cu concentrations were laboratory exposures, not a finished-cosmetic dosage recommendation. The study did not establish clinical hair-growth performance in people using a topical cosmetic product.
Evidence-Aware Comparison
| Evidence Question | GHK-Cu | AHK-Cu | Development Interpretation |
|---|---|---|---|
| Mechanistic / cell research | Substantial | Limited but present | GHK-Cu offers broader background literature |
| Human hair-follicle ex vivo research | Not the defining evidence base | Yes - Pyo 2007 | Supports AHK-Cu scalp/hair R&D positioning |
| Human topical cosmetic evidence | Some published/clinical context but still limited/heterogeneous | No comparable established topical human evidence identified in current source set | Do not present AHK-Cu as clinically proven |
| Direct GHK-Cu vs AHK-Cu human comparison | No strong direct study identified | No strong direct study identified | No potency winner can be claimed |
4. Which Peptide Fits a Skin-Care Brief?
For a facial serum, cream or general skin-care copper-peptide project, GHK-Cu is usually the stronger first candidate. The reason is not that AHK-Cu has been proven ineffective for skin; it is that the GHK-Cu evidence base, cosmetic market familiarity and formulation framework are substantially more developed.
- You need a copper peptide for a premium facial serum or cream.
- Your R&D team wants more published technical context before choosing the active.
- You want a defined first-pass use-level and processing workflow.
- You plan to build a broader GHK-Cu content, product and documentation system around the ingredient.
For current PHYTVA GHK-Cu powder, the first-pass formulation program already has an actionable 0.05-0.20% development range with 0.10% as the recommended starting point. That gives a development team an immediate bench route that AHK-Cu currently does not have at the same evidence confidence.
5. Which Peptide Fits a Scalp or Hair-Care Brief?
AHK-Cu becomes more interesting when the product brief is explicitly scalp- or hair-care-led. Its most distinctive published study is directly connected to human hair follicles and dermal papilla cells, which gives it a clear research rationale for fuller-looking-hair and advanced scalp-serum concepts. [2]
If the brief is 'premium scalp serum with a copper peptide selected specifically for hair-follicle research,' prototype AHK-Cu. If the brief is simply 'add a proven copper peptide to a general skin/scalp formula,' GHK-Cu is the more mature starting platform. Do not describe AHK-Cu as a treatment for hair loss or as clinically superior to GHK-Cu.
6. What About GHK-Cu for Hair and Scalp?
Choosing AHK-Cu powder for a hair-focused concept does not mean GHK-Cu has no scalp relevance. It means the two ingredients arrive at the brief with different evidence stories.
GHK-Cu has a wider biological and cosmetic research base, while AHK-Cu has a more narrowly relevant hair-follicle paper. That distinction is useful for product development: choose the evidence story that matches the claim and positioning strategy you can actually support.
7. Formulation Readiness Is Different
| Development Parameter | GHK-Cu | AHK-Cu |
|---|---|---|
| Current PHYTVA purity/form | 99% powder | 99% powder |
| Water-soluble powder workflow | Established in current PHYTVA formulation program | Commercially described as water soluble; confirm exact grade |
| Use-level recommendation | 0.05-0.20% first-pass; start 0.10% | No independently established universal cosmetic range currently locked |
| pH starting framework | 5.5-6.5 first-pass screen | Use current grade documentation; independent AHK-specific stability data are limited |
| Temperature approach | Cool-down; below 40°C first pass | Prefer cool-down / low-temperature addition; confirm exact grade |
| Compatibility framework | Detailed GHK-Cu compatibility guide available | Do not automatically transfer every GHK-Cu compatibility conclusion |
This difference matters commercially. GHK-Cu can move into bench work immediately with a defined PHYTVA development protocol. AHK-Cu can also be formulated, but its starting use level and operating window should be tied more closely to the current AHK-Cu grade documentation and an AHK-specific bench screen.
8. Do Not Transfer GHK-Cu Dosage to AHK-Cu
The 0.05-0.20% PHYTVA GHK-Cu development range is not automatically an AHK-Cu recommendation. The two molecules are related copper-binding tripeptides, but their evidence and formulation data are not interchangeable.
Likewise, the 10^-12 to 10^-9 M AHK-Cu concentrations in the 2007 hair-follicle paper are not a cosmetic use level. They are laboratory exposure concentrations used in isolated follicles and cultured cells. Converting them directly into a facial or scalp-serum percentage would be scientifically misleading.
9. A Practical Product-Development Decision Matrix
| Your Product Brief | Prototype First | Why | Second Option |
|---|---|---|---|
| Premium anti-aging facial serum | GHK-Cu | Broader skin/cosmetic research and mature formulation framework | AHK-Cu only with a specific differentiated rationale |
| General copper-peptide moisturizer | GHK-Cu | Better default when the brief is broad | AHK-Cu if brand strategy specifically wants the alternate peptide |
| Scalp serum centered on follicle research | AHK-Cu | Direct ex-vivo human follicle / DPC research relevance | GHK-Cu as comparator or broader copper-peptide option |
| Fuller-looking-hair cosmetic concept | AHK-Cu | More specific hair-research story | GHK-Cu if formulation maturity is the higher priority |
| First copper-peptide SKU for a new brand | GHK-Cu | Easier to support technically and commercially | AHK-Cu as later differentiated extension |
| Research-led niche peptide line | AHK-Cu can be attractive | Differentiation and narrower evidence story can be a feature | GHK-Cu for the more established anchor SKU |
If a brand wants to launch both over time, use GHK-Cu as the broader copper-peptide platform and AHK-Cu as the more specialized scalp/hair research-led extension. That creates two distinct product stories instead of forcing both peptides into the same positioning.
10. If You Want to Compare Them in the Lab
Do not design a head-to-head bench test as though it can prove which peptide is biologically superior. A cosmetic lab can compare formulation behavior, not replace missing clinical comparative evidence.
A practical R&D comparison can evaluate:
- Solubility and ease of premix preparation for each exact grade.
- Time-zero color and clarity.
- pH compatibility in the intended base.
- Physical stability over the same test schedule.
- Color drift, haze or precipitation.
- Packaging behavior.
- Cost per finished prototype at the selected grade-specific use level.
Use each ingredient at a defensible grade-specific development level rather than forcing both to the same percentage just to create a symmetrical test. The goal is to decide which ingredient fits the commercial formula better, not to manufacture a false efficacy ranking.
11. What Should Procurement Verify?
| Check | GHK-Cu | AHK-Cu |
|---|---|---|
| Exact peptide identity | Gly-His-Lys copper complex | Ala-His-Lys copper complex |
| Purity / assay | Verify lot COA | Verify lot COA |
| Copper / complex basis | Use current documents | Use current documents |
| Formal cosmetic naming | Current GHK-Cu product documentation | Confirm exact current grade naming; market commonly uses Copper Tripeptide-3 |
| CAS / formula / MW | Use current grade documentation | Do not rely on conflicting public listings; use current grade documentation |
| Use-level guidance | Current PHYTVA GHK protocol available | Confirm AHK-specific TDS / development protocol |
| Live commercial documents | Verify current SKU | Verify current SKU |
12. Bottom-Line Selection
The product is skin-care-led, the copper-peptide brief is broad, you want a more mature evidence/formulation platform, or you need an immediately actionable starting protocol.
The product is specifically scalp/hair-care-led and the development story benefits from AHK-Cu's direct human-hair-follicle ex-vivo and dermal-papilla-cell research. Treat it as a focused R&D choice, not a clinically proven hair-growth ingredient.
13. Next Steps for Product Development
If you choose GHK-Cu, use the GHK-Cu Formulation Guide for the 0.05-0.20% development range, 0.10% starting point and bench workflow.
If the formula contains Vitamin C, strong acids or chelators, continue to the GHK-Cu Stability and Compatibility Guide.
If you choose AHK-Cu, begin with the exact current AHK-Cu product documentation and build an AHK-specific bench plan rather than copying GHK-Cu dosage or pH assumptions.
Primary next step: Compare Trial-Size Copper Peptide Options.
Technical next step: Request Current Product Specifications for the exact peptide grade under evaluation.
Commercial next step: Request Bulk Pricing for Pilot or Production Quantities after the selected peptide passes formulation testing.
Sources
PHYTVA GHK-Cu Blue Powder 99% batch documentation.
